The estimated Net Worth of Narinderjeet Singh is at least $0 dollars as of 8 May 2019. Mr. Singh owns over 7,291 units of Genocea Biosciences Inc stock worth over $0 and over the last 6 years he sold GNCA stock worth over $0. In addition, he makes $0 as Senior Vice President - Pharmaceutical Sciences and Manufacturing at Genocea Biosciences Inc.
Sign up
Mr. Singh GNCA stock SEC Form 4 insiders trading
Narinderjeet has made over 3 trades of the Genocea Biosciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 7,291 units of GNCA stock worth $3,937 on 8 May 2019.
The largest trade he's ever made was exercising 7,291 units of Genocea Biosciences Inc stock on 8 May 2019 worth over $3,937. On average, Narinderjeet trades about 3,646 units every 9 days since 2019. As of 8 May 2019 he still owns at least 61,873 units of Genocea Biosciences Inc stock.
You can see the complete history of Mr. Singh stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Narinderjeet Singh biography
Narinderjeet Singh serves as Senior Vice President - Pharmaceutical Sciences and Manufacturing of the Company. Mr. Narinder manages the manufacturing process development and manufacturing of Genocea’s products. Narinder has extensive experience in process development, scale-up, technical operations, and manufacturing supply chain of biopharmaceuticals. Prior to joining Genocea, Narinder served as Vice President of Drug Product Development and Manufacturing at Momenta Pharmaceuticals from July 2015 to March 2018, responsible for process development and manufacturing of drug products for Momenta’s biosimilars and novel product portfolio. Prior to Momenta, Narinder served as Director, Drug Product Technology at Amgen from June 2007 to July 2015, responsible for process development, commercialization, manufacturing and new technology development for drug products development of Amgen’s biologics-based portfolio. He began his career at Amgen functioning in various junior technical roles, beginning in 1997. Narinder received an Integrated B.Tech/M.Tech. in Biochemical Engineering and Biotechnology from the Indian Institute of Technology, Delhi in 1995, an M.S. in Chemical Engineering from the University of Houston, and an M.B.A. from UCLA Anderson School of Management.
How old is Narinderjeet Singh?
Narinderjeet Singh is 48, he's been the Senior Vice President - Pharmaceutical Sciences and Manufacturing of Genocea Biosciences Inc since 2018. There are 13 older and 3 younger executives at Genocea Biosciences Inc. The oldest executive at Genocea Biosciences Inc is George Siber, 75, who is the Independent Director.
What's Narinderjeet Singh's mailing address?
Narinderjeet's mailing address filed with the SEC is 100 Acorn Park Dr 5th floor, Cambridge, MA 02140, USA.
Insiders trading at Genocea Biosciences Inc
Over the last 11 years, insiders at Genocea Biosciences Inc have traded over $9,875,933 worth of Genocea Biosciences Inc stock and bought 177,421,644 units worth $259,728,894 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Genocea Biosciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $0. The most recent stock trade was executed by Diantha Duvall on 2 June 2022, trading 1,355 units of GNCA stock currently worth $81.
What does Genocea Biosciences Inc do?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
What does Genocea Biosciences Inc's logo look like?
Complete history of Mr. Singh stock trades at Genocea Biosciences Inc
Genocea Biosciences Inc executives and stock owners
Genocea Biosciences Inc executives and other stock owners filed with the SEC include:
-
William Clark,
President, Chief Executive Officer, Director -
William D. Clark M.B.A.,
Pres, CEO & Director -
Girish Aakalu,
Chief Business Officer -
Thomas Davis,
Chief Medical Officer -
Jessica Flechtner,
Chief Scientific Officer -
Dr. Thomas A. Davis,
Chief Medical Officer -
Dr. Girish N. Aakalu Ph.D.,
Chief Bus. Officer -
Katrine Bosley,
Independent Director -
Kenneth Bate,
Independent Chairman of the Board -
George Siber,
Independent Director -
Michael Higgins,
Independent Director -
Ronald Cooper,
Independent Director -
Ali Behbahani,
Independent Director -
Gisela Schwab,
Director -
Narinderjeet Singh,
Senior Vice President - Pharmaceutical Sciences and Manufacturing -
Diantha Duvall,
Chief Financial Officer -
Dr. Jessica Baker Flechtner,
Chief Scientific Officer -
Diantha Duvall,
CFO & Sec. -
Dr. Raymond D. Stapleton Jr.,
Exec. VP of Pharmaceutical Sciences & Manufacturing -
Jacquelyn L. Sumer,
Chief Legal & Compliance Officer -
Kevin Bitterman,
Director -
Jonathan Poole,
Chief Financial Officer -
Seth V Hetherington,
Chief Medical Officer -
Paul Giannasca,
VP of Development -
Stephen J Hoffman,
Director -
Howard Mayer,
Director -
Eric S Hoffman,
Chief Business Officer -
Venture Management Co. V, L...,
-
John Lunger,
Director -
Michael Alfieri,
Principle Financial Officer -
Derek M Meisner,
SENIOR VP AND GENERAL COUNSEL -
Pamela Carroll,
SVP IMMUNO-ONCOLOGY -
David M Mott,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Scott D Sandell,
10% owner -
Mohamad Makhzoumi,
10% owner -
Peter W. Sonsini,
10% owner -
Joshua Makower,
10% owner -
Carmen Chang,
10% owner -
Forest Baskett,
10% owner -
Peter J Barris,
10% owner -
Enterprise Associates 16, L...,
-
Jacquelyn L Sumer,
CHIEF LEGAL & COMPLIANCE OFF -
Robert E Jr Farrell,
VP of Finance & Administration -
Venture Management Co. V, L...,
-
Capital Management, Llc Lux...,
-
Simeon George,
Director -
& Johnson Johnson & Johnson...,
-
Plc Gsk,
10% owner -
Paul Edward Walker,
10% owner -
Jennifer Lyn Herron,
Director -
Raymond D Jr Stapleton,
CHIEF TECHNOLOGY OFFICER